Summarize this clinical trial

Created using ChatSlide

This presentation will explore the EMPA-KIDNEY trial, which investigates the efficacy and safety of Empagliflozin in patients with chronic kidney disease (CKD). Highlighting key findings from Herrington et al. (NEJM 2023), we will discuss the trial's significance in internal medicine, particularly its implications for CKD progression, cardiovascular risk, and its broader applicability beyond albuminuric CKD. This analysis aims to enhance understanding of SGLT2 inhibitors in managing CKD and...